A
Ana Drozdowskyj
Researcher at University of California, San Francisco
Publications - 43
Citations - 6515
Ana Drozdowskyj is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Lung cancer & non-small cell lung cancer (NSCLC). The author has an hindex of 18, co-authored 40 publications receiving 5613 citations.
Papers
More filters
Journal ArticleDOI
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rafael Rosell,Enric Carcereny,Radj Gervais,A. Vergnenegre,Bartomeu Massuti,Enriqueta Felip,Ramon Palmero,Ramon Garcia-Gomez,Cinta Pallares,Jose Miguel Sanchez,Rut Porta,Manuel Cobo,Pilar Garrido,Flavia Longo,Teresa Moran,A. Insa,Filippo de Marinis,Romain Corre,Isabel Bover,Alfonso Illiano,Eric Dansin,Javier de Castro,Michele Milella,Noemi Reguart,Giuseppe Altavilla,Ulpiano Jimenez,Mariano Provencio,Miguel Angel Moreno,J. Terrasa,Jose Muñoz-Langa,Javier Valdivia,Dolores Isla,Manuel Domine,Olivier Molinier,Julien Mazieres,Nathalie Baize,Rosario García-Campelo,Gilles Robinet,Delvys Rodriguez-Abreu,Guillermo Lopez-Vivanco,Vittorio Gebbia,Lioba Ferrera-Delgado,Pierre Bombaron,R. Bernabé,Alessandra Bearz,Angel Artal,Enrico Cortesi,Christian Rolfo,Maria Sanchez-Ronco,Ana Drozdowskyj,Cristina Queralt,Itziar de Aguirre,Jose Luis Ramirez,Jose Javier Sanchez,Miguel Angel Molina,Miquel Taron,Luis Paz-Ares +56 more
TL;DR: Erlotinib has been shown to improve progression-free survival compared with chemotherapy when given as first-line treatment for Asian patients with non-small-cell lung cancer (NSCLC) with activating EGFR mutations as discussed by the authors.
Journal ArticleDOI
The Impact of EGFR T790M Mutations and BIM mRNA Expression on Outcome in Patients with EGFR-Mutant NSCLC Treated with Erlotinib or Chemotherapy in the Randomized Phase III EURTAC Trial
Carlota Costa,Miguel Angel Molina,Ana Drozdowskyj,Ana Giménez-Capitán,Jordi Bertran-Alamillo,Niki Karachaliou,Radj Gervais,Bartomeu Massuti,Jia Wei,Teresa Moran,Margarita Majem,Enriqueta Felip,Enric Carcereny,Rosario García-Campelo,Santiago Viteri,Miquel Taron,Mayumi Ono,Petros Giannikopoulos,Trever G. Bivona,Rafael Rosell +19 more
TL;DR: Low-level pretreatment T790M mutations can frequently be detected and can be used for customizing treatment with T790m-specific inhibitors and can potentially be used as a biomarker of survival in EGFR-mutant NSCLC and for synthetic lethality therapies.
Journal ArticleDOI
Association of EGFR L858R Mutation in Circulating Free DNA With Survival in the EURTAC Trial.
Niki Karachaliou,Clara Mayo de las Casas,Cristina Queralt,Itziar de Aguirre,Boris Melloni,Felipe Cardenal,Ramon Garcia-Gomez,Bartomeu Massuti,Jose Miguel Sanchez,R. Porta,Santiago Ponce-Aix,Teresa Moran,Enric Carcereny,Enriqueta Felip,Isabel Bover,A. Insa,Noemi Reguart,Dolores Isla,Alain Vergnenegre,Filippo de Marinis,Radj Gervais,Romain Corre,Luis Paz-Ares,Daniela Morales-Espinosa,Santiago Viteri,Ana Drozdowskyj,Núria Jordana-Ariza,Jose L uis Ramirez-Serrano,Miguel Angel Molina-Vila,Rafael Rosell +29 more
TL;DR: The peptide nucleic acid-mediated 5´ nuclease real-time polymerase chain reaction (TaqMan) assay used in this study can be used to efficiently assess EGFR mutations in cfDNA and may be a novel surrogate prognostic marker.
Journal ArticleDOI
Co-activation of STAT3 and YES-Associated Protein 1 (YAP1) Pathway in EGFR-Mutant NSCLC
Imane Chaib,Niki Karachaliou,Sara Pilotto,Jordi Codony Servat,Xueting Cai,Xueting Cai,X. Li,Ana Drozdowskyj,Carles Codony Servat,Jie Yang,Jie Yang,Chunping Hu,Chunping Hu,Andrés F. Cardona,Guillermo López Vivanco,Alain Vergnenegre,Jose Miguel Sanchez,Mariano Provencio,Filipo de Marinis,Antonio Passaro,Enric Carcereny,Noemi Reguart,Charo Garcia Campelo,Christina Teixido,Isabella Sperduti,Sonia Rodríguez,Chiara Lazzari,Alberto Verlicchi,Itziar de Aguirre,Cristina Queralt,Jia Wei,Roger Estrada,Raimon Puig de la Bellacasa,Jose Luis Ramirez,Kirstine Jacobson,Henrik J. Ditzel,Mariacarmela Santarpia,Mariacarmela Santarpia,Santiago Viteri,Migual Angel Molina,Caicun Zhou,Peng Cao,Peng Cao,Patrick C. Ma,Trever G. Bivona,Rafael Rosell +45 more
TL;DR: This study uncovers a coordinated signaling network centered on both STAT3 and Src-YAP signaling that limits targeted therapy response in lung cancer and identifies an unforeseen rational upfront polytherapy strategy to minimize residual disease and enhance clinical outcomes.
Journal ArticleDOI
Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients.
Niki Karachaliou,Maria Gonzalez-Cao,G. Crespo,Ana Drozdowskyj,Erika Aldeguer,Ana Giménez-Capitán,Cristina Teixidó,Miguel Angel Molina-Vila,Santiago Viteri,Maria de los Llanos Gil,Salvador Martin Algarra,Elisabeth Pérez-Ruiz,Ivan Marquez-Rodas,Delvys Rodriguez-Abreu,Remedios Blanco,Teresa Puertolas,Maria Angeles Royo,Rafael Rosell +17 more
TL;DR: IFN-γ is an important marker for prediction of response to immune checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma patients and is warranted in order to validate whether IFNG is more accurate than PD-L1.